Next Article in Journal
The Role of JAK2 Abnormalities in Hematologic Neoplasms
Previous Article in Journal
MicroRNAs: Tiny Players with a Big Role in the Pathogenesis of Leukemias and Lymphomas
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reviews
Volume 1
Issue 1
10.4081/hr.2009.e9
hematolrev-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite thumb_up
...
Endorse textsms
...
Comment
Hematology Reviews (renamed as Hematology Reports here since 2010) is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Histone Deacetylase Inhibitors in Multiple Myeloma

by
Sarah Deleu
1,
Eline Menu
1,
Els Van Valckenborgh
1,
Ben Van Camp
1,
Joanna Fraczek
2,
Isabelle Vande Broek
1,
Vera Rogiers
2 and
Karin Vanderkerken
1,*
1
Myeloma Research Center-Brussels, Department of Hematology and Immunology, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, B-1090 Brussels, Belgium
2
Department of Toxicology, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, B-1090 Brussels, Belgium
*
Author to whom correspondence should be addressed.
Hematol. Rev. 2009, 1(1), e9; https://doi.org/10.4081/hr.2009.e9 (registering DOI)
Submission received: 9 February 2009 / Revised: 20 April 2009 / Accepted: 27 April 2009 / Published: 3 June 2009

Abstract

Novel drugs such as bortezomib and high dose chemotherapy combined with stem cell transplantation improved the outcome of multiple myeloma patients in the past decade. However, multiple myeloma often remains incurable due to the development of drug resistance governed by the bone marrow micro-environment. Therefore targeting new pathways to overcome this resistance is needed. Histone deacetylase (HDAC) inhibitors represent a new class of anti-myeloma agents. Inhibiting HDACs results in histone hyperacetylation and alterations in chromatine structure, which, in turn, cause growth arrest differentiation and/or apoptosis in several tumor cells. Here we summarize the molecular actions of HDACi as a single agent or in combination with other drugs in different in vitro and in vivo myeloma models and in (pre)clinical trials.

Share and Cite

MDPI and ACS Style

Deleu, S.; Menu, E.; Van Valckenborgh, E.; Van Camp, B.; Fraczek, J.; Vande Broek, I.; Rogiers, V.; Vanderkerken, K. Histone Deacetylase Inhibitors in Multiple Myeloma. Hematol. Rev. 2009, 1, e9. https://doi.org/10.4081/hr.2009.e9

AMA Style

Deleu S, Menu E, Van Valckenborgh E, Van Camp B, Fraczek J, Vande Broek I, Rogiers V, Vanderkerken K. Histone Deacetylase Inhibitors in Multiple Myeloma. Hematology Reviews. 2009; 1(1):e9. https://doi.org/10.4081/hr.2009.e9

Chicago/Turabian Style

Deleu, Sarah, Eline Menu, Els Van Valckenborgh, Ben Van Camp, Joanna Fraczek, Isabelle Vande Broek, Vera Rogiers, and Karin Vanderkerken. 2009. "Histone Deacetylase Inhibitors in Multiple Myeloma" Hematology Reviews 1, no. 1: e9. https://doi.org/10.4081/hr.2009.e9

APA Style

Deleu, S., Menu, E., Van Valckenborgh, E., Van Camp, B., Fraczek, J., Vande Broek, I., Rogiers, V., & Vanderkerken, K. (2009). Histone Deacetylase Inhibitors in Multiple Myeloma. Hematology Reviews, 1(1), e9. https://doi.org/10.4081/hr.2009.e9

Article Metrics

Back to TopTop